4Filed Jun 21, 8:00 PM ET

United Therapeutics (UTHR) CFO Edgemond James Exercises Options, Sells Shares

$UTHR · UNITED THERAPEUTICS Corp

Research Summary

AI-generated summary of this SEC filing

Updated

United Therapeutics (UTHR) CFO Edgemond James Exercises Options, Sells Shares

What Happened
Edgemond James, CFO and Treasurer of United Therapeutics (UTHR), exercised 10,000 stock options at a strike price of $146.03 (cost $1,460,300) on June 18, 2026 and sold 10,000 shares that same day in multiple open‑market trades for total proceeds of $5,401,489 (average sale price ≈ $540.15). The net cash proceeds after paying the exercise cost were roughly $3.94M. The Form 4 also shows an additional derivative conversion entry for 10,000 shares at $0.00 (see Key Details).

Key Details

  • Transaction date: June 18, 2026. Exercise: 10,000 shares @ $146.03 (acquired) = $1,460,300. Sales: 10,000 shares sold in multiple trades for $5,401,489 (weighted average ≈ $540.15).
  • Sale price range (per footnotes): roughly $533.25 to $549.17 across the various trades; several weighted‑average prices reported with accompanying footnotes.
  • Reporting mechanics: Exercise and subsequent sales were reported as pursuant to a Rule 10b5-1 trading plan entered Oct 31, 2025 (Footnote F1). Multiple footnotes (F2–F14) note the sales were executed in multiple trades and provide price ranges.
  • Shares owned after the transactions: not specified in the provided summary—see the full Form 4 for current holdings.
  • Timeliness: no late filing indicator was provided in the information supplied.

Context

  • This was an option exercise followed by immediate market sales (typical liquidity event following option exercise). Because the sale was executed under a previously established 10b5‑1 plan, it is a prearranged sale program rather than an ad hoc open‑market sale.
  • For retail investors: purchases (insider buys) are often considered more informative about insider sentiment; this filing documents a routine exercise and sale tied to a trading plan and does not on its own indicate a change in insider outlook.
  • For full details (exact post‑transaction holdings, any tax withholding, and the nature of the zero‑price derivative entry), consult the complete Form 4 filing (Accession No. 0001636178-26-000028).